Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial

Summary Background Teriflunomide is a once-daily oral immunomodulator approved for the treatment of relapsing-remitting multiple sclerosis. We aimed to assess the efficacy and safety of teriflunomide in patients with a first clinical episode suggestive of multiple sclerosis. Methods In this randomis...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lancet neurology 2014-10, Vol.13 (10), p.977-986
Hauptverfasser:	Miller, Aaron E, Prof, Wolinsky, Jerry S, Prof, Kappos, Ludwig, MD, Comi, Giancarlo, Prof, Freedman, Mark S, Prof, Olsson, Tomas P, Prof, Bauer, Deborah, MS, Benamor, Myriam, MD, Truffinet, Philippe, MD, O'Connor, Paul W, Prof
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Alanine Transaminase - blood Aspartate Aminotransferases - blood Crotonates - administration & dosage Crotonates - adverse effects Crotonates - therapeutic use Disease Dose-Response Relationship, Drug Double-Blind Method Drug therapy Endpoint Determination Female Humans Immunologic Factors - administration & dosage Immunologic Factors - adverse effects Immunologic Factors - therapeutic use Magnetic Resonance Imaging Male Middle Aged Multiple sclerosis Multiple Sclerosis - drug therapy Neurology Patients Proportional Hazards Models Spinal cord Toluidines - administration & dosage Toluidines - adverse effects Toluidines - therapeutic use Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!